Search results
The 5-year post-recurrence disease-specific survival (PR-DSS) rate was 39.1% in patients with early-stage cervical cancer. The strongest factors for PR-DSS were primary tumour size and the presence of symptoms at diagnosis of recurrence.
A median overall survival exceeding 2·5 years in this population sets a new benchmark in metastatic cervical cancer treatment with BEATcc being the first study to show benefit from PD-L1 therapy in cervical cancer.
16 paź 2024 · Cervical cancer ranks as the fourth most common cancer among women globally, yet prognosis remains dire for those with recurrent or metastatic disease, evidenced by a mere 19% 5-year survival rate. 1 This stark reality underscores the urgent need for novel and enhanced therapeutic options.
23 paź 2023 · The importance of the screening in terms of early detection of disease is supported by the evidence of a remarkable difference in survival rates among the different stages of disease: 5-year overall survival (OS) is 92% in the early stages, 65% and 17% in locally advanced and metastatic diseases respectively, with an estimated OS for the recurre...
2 lut 2021 · The treatment for recurrent cervical cancer remains challenging, and the prognosis of recurrent cervical cancer remains poor, with a 5-year overall survival (OS) rate less than 5% despite intensive therapy (5 – 8) particularly for those who experience a recurrence in a previously irradiated field (9 – 11).
The mainstay of treatment for metastatic cervical cancer has long been platinum-based chemotherapy. 7 Unfortunately, the 5-year survival rate for patients diagnosed with all stages of cervical cancer is 70%, and for patients with metastatic cervical cancer, the survival rate is significantly lower, at 17%. 6 This has led to numerous trials to ...
2 dni temu · Disease-free survival of recurrent high-grade cervical dysplasia (A) and local cervical cancer (B) stratified by treatment (LLETZ and CKC) and surgical radicality. ... whereas we reported on recurrent CIN2-3 and cervical cancer of other histotypes as well, because all (pre)malignant lesions are relevant for oncologic and obstetric outcomes ...
